Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Laure A. De Parseval"'
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
(A) Average body weight of mice treated with each BRAF inhibitor in the experiment depicted in Figure 1C; (B) Encorafenib plasma exposure in mice following the last dose from the experiment depicted in Figure 1C. To estimate daily exposure on the BID
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e582a2e6528fa79c1c59d17f45ea091
https://doi.org/10.1158/1078-0432.22467995
https://doi.org/10.1158/1078-0432.22467995
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Purpose: Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis. We evaluated encorafenib in a phase I study in patients with BRAFi treatment-naïve and pretreated BRA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d33fd78b0f824a6d521ad7699f44e3c
https://doi.org/10.1158/1078-0432.c.6526808
https://doi.org/10.1158/1078-0432.c.6526808
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Biochemical and cellular potency of encorafenib, dabrafenib, and vemurafenib in biochemical and cell-based assays. Purified BRAF V600E kinase domain was used in the biochemical experiments, using kinase-dead MEK1 as a substrate and a phosphorylated M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e51957f9f54ec77b6c8a756ef60a095
https://doi.org/10.1158/1078-0432.22467989
https://doi.org/10.1158/1078-0432.22467989
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Dose-limiting toxicities occurring during cycle 1 in the dose-determining set by dose group, listed per patient.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aca8ca8218081401f1cec59089b4fcc7
https://doi.org/10.1158/1078-0432.22467983
https://doi.org/10.1158/1078-0432.22467983
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Proliferation half maximal inhibitory concentration (IC50) of encorafenib, dabrafenib, and vemurafenib against a panel of BRAF V600-mutant melanoma and colorectal cell lines. Red squares represent BRAF V600E-mutant, and blue squares represent BRAF V6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68828b4950b2f035b05cd735fbbd2b83
https://doi.org/10.1158/1078-0432.22467998.v1
https://doi.org/10.1158/1078-0432.22467998.v1
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Summary of pharmacokinetic parameters (cycle 1 day 1 [C1D1] and cycle 1 day 15 [C1D15]) by treatment group in the dose-escalation phase (QD regimen)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57bd14d32e67c38151e12bf226c3b67b
https://doi.org/10.1158/1078-0432.22467980
https://doi.org/10.1158/1078-0432.22467980
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Best percentage change in sum of longest diameters in target lesion from baseline, by patient, treatment group, and mutation status, in patients with BRAFi-naive (A) and pretreated (B) melanoma. Grouped analysis of patients in the dose-escalation and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0231a102b44c91f9710a9d7e67105389
https://doi.org/10.1158/1078-0432.22467992
https://doi.org/10.1158/1078-0432.22467992
Autor:
Keith T. Flaherty, Laure Moutouh-de Parseval, Michael D Pickard, Carmen Loquai, Victor Sandor, Naoya Yamazaki, Ivana Krajsová, Gabriella Liszkay, Reinhard Dummer, Dirk Schadendorf, Mario Mandalà, Ana Arance, Ralf Gutzmer, Claus Garbe, Paolo A. Ascierto, Helen Gogas, Caroline Robert, Jan Willem de Groot, Caroline Dutriaux, Vanna Chiarion Sileni
Publikováno v:
The Lancet Oncology. 19:1315-1327
Summary Background Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAF V600 -mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoin
Autor:
Vanna Chiarion-Sileni, Ana Arance, Keith T. Flaherty, Ralf Gutzmer, Claus Garbe, Ivana Krajsová, Dirk Schadendorf, Naoya Yamazaki, Caroline Robert, Helen Gogas, Michael D Pickard, Caroline Dutriaux, Laure Moutouh-de Parseval, Jan Willem de Groot, Carmen Loquai, Paolo A. Ascierto, Victor Sandor, Mario Mandalà, Reinhard Dummer, Gabriella Liszkay
Publikováno v:
The Lancet Oncology. 19:603-615
Summary Background Combined BRAF-MEK inhibitor therapy is the standard of care for BRAF V600 -mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibito
Autor:
Michele Moschetta, Jaclyn Davis, Darlene Lu, Laure Moutouh-de Parseval, Luisa Mariconti, Xu Zhu, Nicolas Boissel, Attilio Bondanza, Leyla Shune, Michael Dickinson, Ulrich Jaeger, Boris Engels, Pere Barba, Javier Briones, Anne Laure Marchal, Didier Blaise, Ian W. Flinn, Jennifer Brogdon, Nirav N. Shah, Jennifer Marie Mataraza
Publikováno v:
Blood. 138:740-740
Background: Despite unprecedented efficacy of existing CAR-T cell therapy, many pts fail to respond to the therapy, or relapse after initial response. YTB323 is an autologous CD19-directed CAR-T cell therapy utilizing the FMC63 domain for CD19 recogn